Sildenafil Citrate Tablet, Film Coated
Product Images NDC 71335-3049

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 71335-3049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Logo1)

Image Description (Logo1)
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure depicting the molecular arrangement of sildenafil, the active ingredient in Sildenafil Citrate tablets. The diagram shows atom connectivity including sulfur, nitrogen, oxygen, and carbon atoms with characteristic rings and side chains.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing the effect over 24 hours post-dose of SILDENAFIL 100 mg versus placebo on systolic blood pressure (mmHg). The x-axis represents time in hours after dose, and the y-axis shows changes in systolic blood pressure. Two lines plot the blood pressure changes for each treatment group, with markers indicating data points.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph depicting change in systolic blood pressure (SBP) over 8 hours postdose. Two data series are shown: one for Doxazosin + Placebo and another for Doxazosin + Sildenafil 25 mg. The graph shows changes in SBP (mmHG) on the vertical axis and time postdose (hours) on the horizontal axis, illustrating different SBP responses between the two treatment groups over time.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing change in systolic blood pressure (SBP) over 8 hours postdose. It compares two treatments: Doxazosin with placebo and Doxazosin with Sildenafil 50 mg. The y-axis measures change in SBP (mmHg), and the x-axis shows time in hours after dose. Two trend lines illustrate blood pressure changes across time points.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing the change in mmHg over time after dosing (in hours). It compares two treatments: Doxazosin with Sildenafil 100 mg and Doxazosin with Placebo, with respective data points plotted over an 8-hour period.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph showing plasma concentrations (ng/ml) of sildenafil over time (hours) after dosing with a commercial tablet. The curve peaks around 1 hour and then gradually declines, with measurements extending up to 24 hours post dose.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
A bar chart showing the percentage of patients at endpoint categorized by baseline score and score levels from 0 to 5. The X-axis represents baseline scores from 0 to 5, and the Y-axis shows the percentage of patients at endpoint, ranging from 0% to 80%. Different bar colors correspond to score levels 0 through 5, illustrating patient distribution across these levels.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
A bar chart displaying the percentage of patients at endpoint by baseline score for Sildenafil Citrate 100 mg film-coated tablets. The x-axis represents the baseline score ranging from 0 to 5, while the y-axis shows the percentage of patients at endpoint from 0% to 80%. Multiple bars for each baseline score indicate different groupings or measurements, depicted in varying shades from white to black, with a legend showing categories labeled 0 through 5.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A bar graph showing the percentage of patients reporting improvement by treatment group. Four bars represent placebo (24%), sildenafil citrate 25 mg (63%), sildenafil citrate 50 mg (74%), and sildenafil citrate 100 mg (82%). X-axis labels include treatment groups and patient sample sizes. Y-axis shows percentage from 0 to 100%.*
FDA Label Image

Label (Lbl713353049)

Label (Lbl713353049)
Label for Sildenafil Tablets, USP 100 mg film-coated tablets, containing sildenafil citrate equivalent to 100 mg sildenafil. The label indicates a package count of 10 tablets and states the product is prescription only. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Torrent Pharmaceuticals Ltd. Storage and dispensing instructions are also included, along with NDC 71335-3049-1 and multiple barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.